Codeine
| Evidence Level: L4 | Predicted Indications: 4 |
Table of Contents
Codeine: From Allergic Rhinitis and Headache Disorders to Nasal Cavity Disease
One-Sentence Summary
Codeine is an opioid analgesic and cough suppressant, listed in the knowledge graph for conditions such as allergic rhinitis, pharyngitis, common cold and headache disorder. The TxGNN model predicts it may be effective for nasal cavity disease, but there are 0 clinical trials and only 1 publication (a case report describing a possible adverse-event association, not therapeutic evidence). The prediction is best regarded as a model signal with very weak supporting evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, pharyngitis, common cold, rhinitis, nasopharyngitis, headache disorder (from the knowledge graph; no approved indication text is available from the New Zealand licences) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L4 |
| New Zealand Market Status | Cancelled only |
| Number of Authorizations | 3 (all cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Codeine is known to be an opioid agonist at the mu-opioid receptor (OPRM1), with analgesic and antitussive effects. It is also used as a cough suppressant and for pain, and has been linked to the upper respiratory and headache indications above.
The very high TxGNN score (0.999) most likely reflects network proximity to the original rhinitis and common cold indications rather than a distinct mechanism. Codeine's antitussive and mild secretion-drying effects offer only a weak rationale for structural nasal disease.
The only publication is a case report of rhinolithiasis formed around a hardened codeine and opium mixture (an "opioma"). This points to a possible adverse-event association, not a therapeutic benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 17315836 | 2007 | Case report | Ear, Nose & Throat Journal | Unusual unilateral rhinolith formed around a foreign body that was a hardened codeine and opium mixture ("opioma") in a 21-year-old man; not evidence of efficacy |
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 2643200 | Noumed | Tab 15 mg | Not available (cancelled) |
| 2643219 | Noumed | Tab 30 mg | Not available (cancelled) |
| 2643227 | Noumed | Tab 60 mg | Not available (cancelled) |
Safety Considerations
- Contraindication-related conditions (from the knowledge graph, not package insert text): hypertension, liver failure and liver disease, epilepsy, insomnia, chronic obstructive pulmonary disease, anxiety disorder, dysthymic disorder, psychotic and other mental disorders, inherited porphyria, kidney disease, pancreatitis, gallbladder disease, thrombocytopenia, hypothyroidism/myxedema, peptic ulcer disease, inflammatory bowel disease, gastritis, dermatitis herpetiformis.
- Pharmacological interaction: Codeine acts as a ligand at the mu-opioid receptor (OPRM1). No drug-drug interaction details are available beyond this.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high, but it appears to be driven by network proximity to related respiratory indications. There are no clinical trials, and the only publication is a case report suggesting an adverse association. All New Zealand licences are cancelled, which further limits practical feasibility.
To proceed, the following is needed:
- Mechanism of action data and a plausible mechanistic rationale for nasal cavity disease
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Controlled clinical evidence showing therapeutic benefit in nasal disease
- Confirmation of whether any valid New Zealand product or route of administration would be available
Note on other predictions: Lower-ranked predictions (acute laryngopharyngitis, trigeminal autonomic cephalalgia, allergic urticaria) were also reviewed. They carry no supportive therapeutic evidence. Codeine is a known mast-cell histamine releaser and a cause of urticaria, so the allergic urticaria prediction is likely a false-positive signal. Opioids are also not recommended for cluster headache-type conditions.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.